Drugs / Human Rabies Immune Globulin
Human Rabies Immune Globulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT01610362 | Jun 2012 → Apr 2018 | rabies | Queen Saovabha Memorial Institute | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03961555 Comparator | Sep 2019 → Dec 2021 | rabies | Synermore Biologics Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT04644484 Comparator | Sep 2020 → Jun 2022 | Rhabdoviridae infectious disease, rabies | Synermore Biologics (Suzhou) Co., Ltd. | Completed | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Rabies Immune Globulin | “Human Rabies Immune Globulin (HRIG)” NCT03961555 ↗ |
| Known as | HRIG | “20 IU/kg of human rabies immune globulin (HRIG).” NCT01610362 ↗2“Human Rabies Immune Globulin (HRIG)” NCT04644484 ↗ “Human Rabies Immune Globulin (HRIG)” NCT03961555 ↗ |
| Known as | HyperRab | “HRIG (HyperRab)” NCT03961555 ↗ |
| Modality | Protein / enzyme biologic | “HyperRab® (a licensed Rabies immune globulin from human sources, HRIG)” NCT03961555 ↗ |
| Route | Intramuscular | “Human Rabies Immune Globulin (HRIG): Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible” NCT04644484 ↗ |
| Route | Other | “Human Rabies Immune Globulin (HRIG): Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible” NCT04644484 ↗ |
| Route | Subcutaneous | “Human Rabies Immune Globulin (HRIG): Interventions: are administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible” NCT04644484 ↗ |